New discovery platform for antigen-specific monoclonal antibodies

Cell Signaling Technology, Inc. (CST) of Danvers, MA is pleased to announce the development of a new discovery platform for antigen-specific monoclonal antibodies. This novel antibody discovery technology, named NG-XMTTM, harnesses the power of proteomics to identify and clone antigen-specific monoclonal antibodies directly from the circulating serum of an immunized animal. As described in the May print issue of Nature Biotechnology [30, 447 - 452 (2012)], NG-XMTTM technology enables the isolation of monoclonal antibodies with antigen-specific activities that recapitulate or surpass those of the original affinity-purified polyclonal antibodies found in the sera of immunized rabbits and mice.

“CST is exploring all avenues to bring this technology to market and to impact patients' lives.”

"Our NG-XMTTM proteomics-based technology is faster and more efficient than traditional hybridoma-based methods, " said Roberto D. Polakiewicz, Ph.D., CST Chief Scientific Officer. "Moreover, our proprietary and patent pending technology can be applied to the development of therapeutically relevant human monoclonal antibodies for vaccine development and for understanding basic questions in immunology. CST has long been an industry leader in the development and manufacture of high performance antibodies for basic and clinical research, and we are excited to announce this breakthrough in monoclonal antibody technology."

"NG-XMT™ technology is ready for commercialization," said Fenel M. Eloi, CST Chief Operating Officer. "CST is exploring all avenues to bring this technology to market and to impact patients' lives."

Source:

Cell Signaling Technology, Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cell Signaling Technology. (2019, June 20). New discovery platform for antigen-specific monoclonal antibodies. News-Medical. Retrieved on August 25, 2019 from https://www.news-medical.net/news/20120511/New-discovery-platform-for-antigen-specific-monoclonal-antibodies.aspx.

  • MLA

    Cell Signaling Technology. "New discovery platform for antigen-specific monoclonal antibodies". News-Medical. 25 August 2019. <https://www.news-medical.net/news/20120511/New-discovery-platform-for-antigen-specific-monoclonal-antibodies.aspx>.

  • Chicago

    Cell Signaling Technology. "New discovery platform for antigen-specific monoclonal antibodies". News-Medical. https://www.news-medical.net/news/20120511/New-discovery-platform-for-antigen-specific-monoclonal-antibodies.aspx. (accessed August 25, 2019).

  • Harvard

    Cell Signaling Technology. 2019. New discovery platform for antigen-specific monoclonal antibodies. News-Medical, viewed 25 August 2019, https://www.news-medical.net/news/20120511/New-discovery-platform-for-antigen-specific-monoclonal-antibodies.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
CST introduces HER3 antibody for studying HER2-mediated breast, lung and ovarian tumors